1. |
马代全, 黄桂蛟, 田道蓉, 等. 急性重症胰腺炎合并胰性脑病的临床诊治. 西部医学, 2012, 24(7):1320-1321, 1324.
|
2. |
王艳茹, 麻继臣, 张晓岚, 等. 胰性脑病的诊治进展. 医学综述, 2010, 16(4):595-598.
|
3. |
Sharma V, Sharma R, Rana SS, et al. Pancreatic encephalopathy:an unusual cause of asterixis. JOP, 2014, 15(4):383-384.
|
4. |
江少娜. 胰性脑病的研究现状. 实用心脑肺血管病杂志, 2012, 20(2):373-375.
|
5. |
孔雷, 韩天权, 汤耀卿, 等. 对胰性脑病病因和发病机制的认识. 中国现代普通外科进展, 2002, 5(2):68-70.
|
6. |
Qiu F, Lu XS, Huang YK. Protective effect of low-molecular-weight heparin on pancreatic encephalopathy in severe acute pancreatic rats. Inflamm Res, 2012, 61(11):1203-1209.
|
7. |
Hornik A, Rodriguez Porcel FJ, Agha C, et al. Central and extrapontine myelinolysis affecting the brain and spinal cord. An unusual presentation of pancreatic encephalopathy. Front Neurol, 2012, 3:135.
|
8. |
Mameli G, Cossu D, Cocco E, et al. Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. J Neuroimmunol, 2014, 270(1-2):51-55.
|
9. |
刘小丰, 钱祝银, 苗毅, 等. 中枢脱髓鞘病变的免疫机制与胰性脑病. 中国现代普通外科进展, 2004, 7(3):129-130.
|
10. |
覃惠洵, 刘琳琳, 郝洪军, 等. OCB、抗MBP抗体及抗MOG抗体在中枢神经系统炎性脱髓鞘疾病诊断中的意义. 中国实用神经疾病杂志, 2014, 17(8):11-13.
|
11. |
Hedegaard CJ, Chen N, Sellebjerg F, et al. Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis:a role in regulating cytokine responses to MBP. Immunology, 2009, 128(1 Suppl):e451-e461.
|
12. |
郭遂成, 杨敬端. 胰性脑病24例临床治疗观察. 中国社区医师(医学专业), 2013, 15(9):40.
|
13. |
侯杰. 重症急性胰腺炎并胰性脑病的临床分析. 中国医药指南, 2013, 11(11):433-434.
|
14. |
周志军. 胰性脑病一例. 腹部外科, 2013, 26(3):214.
|
15. |
周建峰. 86例重症急性胰腺炎临床预后相关分析. 医药前沿, 2012, 29:100-101.
|
16. |
Cosmi L, Liotta F, Maggi E, et al. Th17 and non-classic Th1 cells in chronic inflammatory disorders:two sides of the same coin. J Int Arch Allergy Immunol, 2014, 164(3):171-177.
|
17. |
Hidaka Y, Inaba Y, Matsuda K, et al. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis:IFN-gamma and TNF-alpha are important participants in the first attack but not in the relapse. J Neurol Sci. 2014, 340(1-2):117-122.
|
18. |
Belogurov A Jr, Kudriaeva A, Kuzina E, et al. Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradation. J Biol Chem, 2014, 289(25):17758-17766.
|
19. |
Yamasaki R. The role of microglia in inflammatory demyelination lesion in the central nervous system. Rinsho Shinkeigaku, 2014, 54 (12):981-983.
|
20. |
Kersh AE, Edwards LJ, Evavold BD, et al. Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread. J Immunol, 2014, 193(9):4429-4438.
|
21. |
Bsibsi M, Peferoen LA, Holtman IR, et al. Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-gamma and alpha B-crystallin. Acta Neuropathol, 2014, 128(2):215-229.
|
22. |
Kaltsonoudis E, Zikou AK, Voulgari PV, et al. Neurological adverse events in patients receiving anti-TNF therapy:a prospective imaging and electrophysiological study. Arthritis Res Ther, 2014, 16(3):R125.
|
23. |
Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, et al. Efficacy of fish oil on serum of TNF alpha, IL-1 beta, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev, 2013, 2013:709493.
|
24. |
Li J, Yang WJ, Huang LM, et al. Immunomodulatory therapies for acute pancreatitis. World J Gastroenterol, 2014, 20(45):16935-16947.
|
25. |
Hori T, Uemoto S, Walden LB, et al. Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy:A pilot study in mice. Hepatol Res, 2014, 44(6):651-662.
|
26. |
Clancy-Thompson E, King LK, Nunnley LD, et al. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res, 2013, 1(5):332-339.
|
27. |
Doronin VB, Parkhomenko TA, Castellazzi M, et al. Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis. PLoS One. 2014, 9(9):e107807.
|
28. |
Kaltsonoudis E, Zikou A K, Voulgari P V, et al. Neurological adverse events in patients receiving anti-TNF therapy:a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014, 16(3):R125.
|
29. |
Ferreira T B, Hygino J, Barros P O, et al. Endogenous interleukin-6 amplifies interleukin-17 production and corticoid-resistance in peripheral T cells from patients with multiple sclerosis. Immunology, 2014, 143(4):560-568.
|
30. |
Trinschek B, Luessi F, Haas J, et al. Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoS One, 2013, 8(10):e77634.
|
31. |
Wullschleger A, Kapina V, Molnarfi N, et al. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS One, 2013, 8(8):e72399.
|